P/B
—
Alector
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
$246.8M
Market Cap • 10/30/2026
2013
(13 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
17,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
246,8M
EV
106,7M
EV/Revenue
7,7
EV/EBITDA
-0,9
EV/EBIT
-0,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-8,2%
Total Yield
-8,2%
Payout
0%
Retained Earnings
-1B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
715,1%
Capex/Revenue
1,2%
Capex/D&A
3,5%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
10,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-8,3%
CAGR Op. Income 5Y
-10%
CAGR Net Income 5Y
-11,1%
CAGR EPS 5Y
-16,3%
CAGR OCF 5Y
-3,2%
Leverage
N.D./EBITDA
1,1
Debt/Equity
0%
Current Ratio
5,3
Quick Ratio
5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!